Maksimenko A V, Tischenko E G, Petrov A D, Petrova M L, Golubykh V L
Institute of Experimental Cardiology, Cardiology Research Center, Moscow, Russia.
Appl Biochem Biotechnol. 1996 Oct-Nov;61(1-2):123-8. doi: 10.1007/BF02785694.
Conjunctive administration of the tissue-type plasminogen activator (t-PA) and the urokinase-fibrinogen covalent conjugate (UK-Fbg) was studied by the example of venous thrombosis in dogs. Comparing the effect of separate use of the two components, we observed the potentiation of thrombolytic effect induced by an i.v. bolus infusion administration of the tissue-type plasminogen activator (1 and 4 mg, respectively) combined with a bolus administration 15 min after the first injection of the 25,000 IU UK-Fbg. Faster-action and potentiation effects of thrombolysis were observed with the same administration scheme when the t-PA was used as bolus infusion (1 and 1 mg, respectively) combined with a bolus of the 250,000 IU fibrinogen-modified urokinase. The findings indicate an approach to the development of efficient thrombolytic compositions.
以犬静脉血栓形成为例,研究了组织型纤溶酶原激活剂(t-PA)与尿激酶-纤维蛋白原共价缀合物(UK-Fbg)的联合给药。比较两种成分单独使用的效果时,我们观察到静脉推注组织型纤溶酶原激活剂(分别为1毫克和4毫克)并在首次注射25,000国际单位UK-Fbg 15分钟后推注给药,可增强溶栓效果。当t-PA作为推注输注(分别为1毫克和1毫克)与2